Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928

Multiple Myeloma

COMPLETED PHASE3

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

NCT01541332

Multiple Myeloma

UNKNOWN PHASE1/PHASE2

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

NCT03170882

Relapsed and/or Refractory Multiple Myeloma

COMPLETED PHASE2

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT07284758

Multiple Myeloma Relapsed/Refractory Multiple Myeloma

RECRUITING PHASE2

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT00378209

Multiple Myeloma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is the initial study of TH-302 in subjects with relapsed/refractory multiple myeloma. It is an open-label dose-escalation study to determine the DLTs, MTD, safety and preliminary efficacy of TH-302 and dexamethasone with a Simon two-stage expansion at the MTD. The study will also investigate the DLTs, MTD, safety and preliminary efficacy of TH-302, dexamethasone and bortezomib; and the DLTs, MTD, safety and preliminary efficacy of TH-302, dexamethasone and pomalidomide. As such, the study is separated into four parts. Treatment will be administered until disease progression or unacceptable toxicity, or 12 cycles (Arm A, Arm B and Arm C) or 9 cycles (Arm D) have been completed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monotherapy TH-302 Dose Escalation

Group Type EXPERIMENTAL

TH-302

Intervention Type DRUG

TH-302 and Dexamethasone Dose Expansion

Group Type EXPERIMENTAL

TH-302 and Dexamethasone

Intervention Type DRUG

TH-302 Dose Escalation and Dexamethasone with Bortezomib

Group Type EXPERIMENTAL

TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib

Intervention Type DRUG

TH-302 Dose Escalation and Dexamethasone with Pomalidomide

Group Type EXPERIMENTAL

TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TH-302

Intervention Type DRUG

TH-302 and Dexamethasone

Intervention Type DRUG

TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib

Intervention Type DRUG

TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. At least 18 years of age.
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee.
3. Relapsed/refractory multiple myeloma for which no standard therapy options are anticipated to result in a durable remission.
4. Receipt of at least two prior therapies as indicated by protocol
5. Subjects with measurable disease
6. ECOG performance status of less than or equal to 2
7. Acceptable liver function
8. Acceptable renal function
9. Acceptable hematologic status
10. For Part A, B, C subjects: Women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner as indicated by protocol For Part D subjects: a negative serum pregnancy test is required within 10- 14 days prior to initiating with pomalidomide, AND a negative serum pregnancy test within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control at least 28 days before she starts taking pomalidomide.

Women of childbearing potential must enroll into and follow all requirements of the POMALYST REMS program, which includes adhering to the scheduled pregnancy testing.

Men must agree to use a latex or synthetic condom during sexual contact with women of child bearing potential even if they have had a vasectomy.

All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure, or when a female patient misses her period or if there is any abnormality in her menstrual bleeding.
11. Subjects must adhere to the study visit schedule and other protocol requirements and receive outpatient therapy and laboratory monitoring at the institute that administers the study drug.

Exclusion Criteria

1. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes.)
2. Waldenstrom's macroglobulinemia
3. Localized radiation therapy to only measurable disease site(s) within 2 weeks of treatment
4. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, or unstable arrhythmia
5. Significant neuropathy (Grade 3 or 4, or Grade 2 with pain) at the time of enrollment or within 14 days before enrollment
6. Symptomatic brain metastases (unless previously treated and well controlled for a period of ≥ 3 months)
7. Severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the investigator any physiological state leading to hypoxemia
8. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy within 14 days prior to the first dose
10. Previously treated malignancies, except for adequately treated non-melanoma skin cancer (basal cell or squamous cell), in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
11. Subjects who participated in an investigational drug or device study within 2 weeks prior to study entry
12. Known or suspected active infection with HIV, hepatitis A, hepatitis B, or hepatitis C
13. Subjects who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation similar to TH-302, bortezomib (for subjects enrolled in Part C only), pomalidomide (Part D), dexamethasone or pimonidazole
14. Females who are pregnant or breast-feeding
15. Concomitant psychiatric disease or medical condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
16. Unwillingness or inability to comply with the study protocol for any reason
17. Previous cytotoxic therapies for multiple myeloma within 3 weeks prior to study entry (2 weeks for biologic, novel therapy or corticosteroids)
18. Subjects who have been on hormone replacement less than 2 months (subjects on hormone replacement for at least 2 months will not be excluded provided the HRT regimen remains unchanged during the conduct of the study).
19. Prior peripheral stem cell transplant within 12 weeks of the start of study
20. Epilepsy or other convulsive disorder requiring active management
21. Prior therapy with a pomalidomide-containing regimen
22. Subjects on strong inducers or strong inhibitors of cytochrome P450 CYP3A4 or CYP1A2
23. Any other medical condition that in opinion of investigator would place patient at increased risk for toxicity during pomalidomide treatment (i.e. history of recurrent or serious thromboembolic events)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No